Nolasco-Cardona María Elena1,2*, López-Paz Sisa2, Rivera-Mejía Ronald Virgilio2, Murga Gladys Beatriz1 and Gil José Rodolfo1
1Anatomical and Clinical Pathology, Roosevelt Hospital, Guatemala City, Guatemala
2Universidad Nacional Autónoma de Honduras, Hospital Escuela Universitario, Tegucigalpa, M.D.C, Honduras, Guatemala
*Corresponding Author: Nolasco-Cardona María Elena, Anatomical and Clinical Pathology, Roosevelt Hospital, Guatemala City, Guatemala.
Received: December 30, 2022; Published: February 16, 2023
A 35-year-old, male with gradual bilateral decrease in visual acuity of 5-weeks history of evolution. The campimetry showed 0% of visual field in the left eye and 84% in the right eye, with temporal hemianopsia, imaging studies were performed to rule out any lesion in optic chiasm. Both computerized tomography (CT) and magnetic resonance imaging (MRI) of the brain showed inflammation at the intersection of the optic nerve to the brain (optic neuritis). Likewise, an immunological study was performed to detect the acuaporin-4 antibodies (antiAQP4), being this result positive; so, the diagnosis of optical neuromyelitis (NMO) was concluded. The patient was treated first with steroids at high doses, but no improvement was observed. Therefore, based on the treatment guidelines of the American Apheresis Society (ASFA), Therapeutic Plasma Exchange (TPE)/therapeutic plasmapheresis was decided, giving positive results from the first session.
Keywords: Neuromyelitis Optica; Autoantibodies; Plasmapheresis
Citation: Nolasco-Cardona María Elena., et al. “Therapeutic Plasmapheresis in Optical Neuromyelitis”.Acta Scientific Medical Sciences 7.3 (2023): 133-135.
Copyright: © 2022 Nolasco-Cardona María Elena., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.